• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Candel Therapeutics, Inc. - Common Stock (NQ:CADL)

    5.330 -0.090 (-1.66%)
    Streaming Delayed Price Updated: 4:00 PM EDT, Oct 17, 2025 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Press Releases about Candel Therapeutics, Inc. - Common Stock

    < Previous 1 2 3 Next >
    Candel Therapeutics Appoints Leading Systems Immunology Expert Bali Pulendran, Ph.D., to Research Advisory Board
    From Candel Therapeutics
    Via GlobeNewswire
    Candel Therapeutics Enters into $130 Million Term Loan Facility with Trinity Capital Inc.
    From Candel Therapeutics
    Via GlobeNewswire
    Candel Therapeutics Announces Positive Interim Data After Repeated Administration of CAN-3110 in Recurrent Glioblastoma and Announces Publication in Science Translational Medicine
    From Candel Therapeutics
    Via GlobeNewswire
    Candel Therapeutics to Present at the SITC 2025 Annual Meeting
    From Candel Therapeutics
    Via GlobeNewswire
    Candel Therapeutics Presents Phase 3 Clinical Trial of CAN-2409 in Localized Prostate Cancer at ASTRO 2025
    From Candel Therapeutics
    Via GlobeNewswire
    Candel Therapeutics to Present Phase 3 Results of CAN-2409 in Localized Prostate Cancer at ASTRO 2025
    From Candel Therapeutics
    Via GlobeNewswire
    Candel Therapeutics Appoints Renowned Immunotherapy Pioneer Carl H. June, M.D., to Research Advisory Board
    From Candel Therapeutics
    Via GlobeNewswire
    Candel Therapeutics to Participate in Upcoming Investor Conferences in September
    From Candel Therapeutics
    Via GlobeNewswire
    Candel Therapeutics Reports Second Quarter 2025 Financial Results and Recent Corporate Highlights
    From Candel Therapeutics
    Via GlobeNewswire
    Candel Therapeutics to Present at the Canaccord Genuity 45th Annual Growth Conference
    From Candel Therapeutics
    Via GlobeNewswire
    Candel Therapeutics Receives EMA Orphan Designation for CAN-2409 for the Treatment of Pancreatic Cancer
    From Candel Therapeutics
    Via GlobeNewswire
    Candel Therapeutics Expands Russell Index Presence with Addition to Multiple Value-Oriented Indexes in 2025 Reconstitution
    From Candel Therapeutics
    Via GlobeNewswire
    Candel Therapeutics Announces $15 million Registered Direct Offering of Common Stock
    From Candel Therapeutics
    Via GlobeNewswire
    Candel Therapeutics Appoints Charles Schoch as Chief Financial Officer
    Interim CFO elevated to permanent role after demonstrating exceptional financial leadership, guiding the company through major operational and financial milestones 
    From Candel Therapeutics
    Via GlobeNewswire
    Candel Therapeutics Appoints Maha Radhakrishnan, M.D., to its Board of Directors
    Appointment of seasoned strategic industry executive strengthens the Board of Directors as Candel advances toward Biologics License Application submission and commercial development 
    From Candel Therapeutics
    Via GlobeNewswire
    Candel Therapeutics Receives FDA Regenerative Medicine Advanced Therapy Designation for CAN-2409 for the Treatment of Prostate Cancer
    From Candel Therapeutics
    Via GlobeNewswire
    Candel Therapeutics to Host Investor Conference Call Featuring Expert Clinical Perspectives on CAN-2409 Phase 3 Prostate Cancer Data Following 2025 ASCO Presentation
    From Candel Therapeutics
    Via GlobeNewswire
    Candel Therapeutics Presents Positive Phase 3 CAN-2409 Results in Localized Prostate Cancer at ASCO 2025
    From Candel Therapeutics
    Via GlobeNewswire
    Candel Therapeutics Reports First Quarter 2025 Financial Results and Recent Corporate Highlights
    From Candel Therapeutics
    Via GlobeNewswire
    Candel Therapeutics to Present at Upcoming Investor Conferences
    From Candel Therapeutics
    Via GlobeNewswire
    Candel Therapeutics Announces Oral Presentation of Positive Phase 3 CAN-2409 Results in Localized Prostate Cancer at ASCO 2025
    From Candel Therapeutics
    Via GlobeNewswire
    Candel Therapeutics Announces Publication of Phase 1b Clinical Trial Data on the Combination of CAN-2409 and Nivolumab plus Standard of Care in Newly Diagnosed High-Grade Glioma Patients
    Data published in Neuro-Oncology demonstrate promising safety profile and potential survival benefit when combining CAN-2409 and nivolumab with standard of care 
    From Candel Therapeutics
    Via GlobeNewswire
    Candel Therapeutics and IDEA Pharma Announce Strategic Partnership to Advance Path-to-Market Commercialization Efforts for CAN-2409
    From Candel Therapeutics
    Via GlobeNewswire
    Candel Therapeutics Reports Both Prolonged Median Overall Survival and Long Tail of Survival in Phase 2a Clinical Trial of CAN-2409 in Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Non-Responsive to Immune Checkpoint Inhibitor (ICI) Treatment
    From Candel Therapeutics
    Via GlobeNewswire
    Candel Therapeutics Appoints Renowned Pancreatic Cancer Expert, Elizabeth M. Jaffee, M.D., to Research Advisory Board
    From Candel Therapeutics
    Via GlobeNewswire
    Candel Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Corporate Highlights
    From Candel Therapeutics
    Via GlobeNewswire
    Candel Therapeutics Announces Positive Final Survival Data from Randomized Controlled Phase 2 Clinical Trial of CAN-2409 in Non-Metastatic Pancreatic Cancer
    From Candel Therapeutics
    Via GlobeNewswire
    Candel Therapeutics Provides Corporate Update and Highlights Strong Pipeline Momentum and Key Value Drivers for 2025
    From Candel Therapeutics
    Via GlobeNewswire
    Candel Therapeutics Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares
    From Candel Therapeutics
    Via GlobeNewswire
    Candel Therapeutics Announces Pricing of Public Offering
    From Candel Therapeutics
    Via GlobeNewswire
    < Previous 1 2 3 Next >
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.